Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Intermittent Tamsulosin

Phase 3Small molecule

MMansoura University

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

BPHNot yet recruiting

BPHPhase 3

Not yet recruiting

Timeline

Expected Milestones

Q1 2027

Post-ApprovalNot yet recruiting

BPH

NCT07308002

Clinical

Trials by Indication[1]

BPH1 trial

Intermittent vs Daily Tamsulosin for LUTS/BPH

Not yet recruiting·MMansoura University·Phase 4·NCT07308002·288 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Intermittent Tamsulosin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intermittent Tamsulosin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intermittent Tamsulosin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mansoura University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMansoura University

Related News